Win­ners and losers at #ES­MO18

MU­NICH — As­traZeneca has fol­lowed up on its break­through ap­proval for Lyn­parza — the first of the PARP wave that ar­rived on the mar­ket 4 years ago — with the roll­out of im­pres­sive front­line da­ta for ovar­i­an can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.